TY - JOUR
T1 - Myo-inositol alters the effects of glucose, leptin and insulin on placental palmitic acid and oleic acid metabolism
AU - Watkins, Oliver C.
AU - Pillai, Reshma Appukuttan
AU - Selvam, Preben
AU - Yong, Hannah E.J.
AU - Cracknell-Hazra, Victoria K.B.
AU - Sharma, Neha
AU - Cazenave-Gassiot, Amaury
AU - Bendt, Anne K.
AU - Godfrey, Keith M.
AU - Lewis, Rohan M.
AU - Wenk, Markus R.
AU - Chan, Shiao Yng
N1 - Publisher Copyright:
© 2023 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
PY - 2023/9/15
Y1 - 2023/9/15
N2 - Abstract: Well-regulated placental palmitic acid (PA) and oleic acid (OA) metabolism is vital for optimal placental function and fetal development, but dysregulation occurs with gestational diabetes (GDM). We hypothesized that such dysregulation might arise from increased maternofetal glucose, leptin or insulin concentrations present in GDM, and that dysregulated PA and OA lipid metabolism could be moderated by myo-inositol, a natural polyol and potential GDM intervention. Placental explants from 21 women were incubated with stable isotope-labelled 13C-PA or 13C-OA for 48 h. Explants were treated with glucose (5, 10 mm) or leptin (13 nm) or insulin (150 nm) in combination with myo-inositol (0.3, 30, 60 μm). Forty-seven 13C-PA lipids and 37 13C-OA lipids were measured by liquid chromatography–mass spectrometry (LCMS). Compared with controls (5 mm glucose), glucose (10 mm) increased 19 13C-OA lipids and nine 13C-PA lipids, but decreased 13C-OA phosphatidylethanolamine 38:5 and 13C-PA phosphatidylethanolamine 36:4. The effects of leptin and insulin were less prominent than glucose, with leptin increasing 13C-OA acylcarnitine 18:1, and insulin increasing four 13C-PA triacylglycerides. Most glucose, leptin and insulin-induced alterations in lipids were attenuated by co-incubation with myo-inositol (30 or 60 μm), with attenuation also occurring in all subgroups stratified by GDM status and fetal sex. However, glucose-induced increases in acylcarnitine were not attenuated by myo-inositol and were even exaggerated in some instances. Myo-inositol therefore appears to generally act as a moderator, suppressing the perturbation of lipid metabolic processes by glucose, leptin and insulin in placenta in vitro. Whether myo-inositol protects the fetus and pregnancy from unfavourable outcomes requires further research. (Figure presented.). Key points: Incubation of placental explants with additional glucose, or to a lesser extent insulin or leptin, alters the placental production of 13C-lipids from 13C-palmitic acid (PA) and 13C-oleic acid (OA) in vitro compared with untreated controls from the same placenta. Co-incubation with myo-inositol attenuated most alterations induced by glucose, insulin or leptin in 13C-lipids, but did not affect alterations in 13C-acylcarnitines. Alterations induced by glucose and leptin in 13C-PA triacylglycerides and 13C-PA phospholipids were influenced by fetal sex and gestational diabetes status, but were all still attenuated by myo-inositol co-incubation. Insulin differently affected 13C-PA triacylglycerides and 13C-PA phospholipids depending on fetal sex, with alterations also attenuated by myo-inositol co-incubation.
AB - Abstract: Well-regulated placental palmitic acid (PA) and oleic acid (OA) metabolism is vital for optimal placental function and fetal development, but dysregulation occurs with gestational diabetes (GDM). We hypothesized that such dysregulation might arise from increased maternofetal glucose, leptin or insulin concentrations present in GDM, and that dysregulated PA and OA lipid metabolism could be moderated by myo-inositol, a natural polyol and potential GDM intervention. Placental explants from 21 women were incubated with stable isotope-labelled 13C-PA or 13C-OA for 48 h. Explants were treated with glucose (5, 10 mm) or leptin (13 nm) or insulin (150 nm) in combination with myo-inositol (0.3, 30, 60 μm). Forty-seven 13C-PA lipids and 37 13C-OA lipids were measured by liquid chromatography–mass spectrometry (LCMS). Compared with controls (5 mm glucose), glucose (10 mm) increased 19 13C-OA lipids and nine 13C-PA lipids, but decreased 13C-OA phosphatidylethanolamine 38:5 and 13C-PA phosphatidylethanolamine 36:4. The effects of leptin and insulin were less prominent than glucose, with leptin increasing 13C-OA acylcarnitine 18:1, and insulin increasing four 13C-PA triacylglycerides. Most glucose, leptin and insulin-induced alterations in lipids were attenuated by co-incubation with myo-inositol (30 or 60 μm), with attenuation also occurring in all subgroups stratified by GDM status and fetal sex. However, glucose-induced increases in acylcarnitine were not attenuated by myo-inositol and were even exaggerated in some instances. Myo-inositol therefore appears to generally act as a moderator, suppressing the perturbation of lipid metabolic processes by glucose, leptin and insulin in placenta in vitro. Whether myo-inositol protects the fetus and pregnancy from unfavourable outcomes requires further research. (Figure presented.). Key points: Incubation of placental explants with additional glucose, or to a lesser extent insulin or leptin, alters the placental production of 13C-lipids from 13C-palmitic acid (PA) and 13C-oleic acid (OA) in vitro compared with untreated controls from the same placenta. Co-incubation with myo-inositol attenuated most alterations induced by glucose, insulin or leptin in 13C-lipids, but did not affect alterations in 13C-acylcarnitines. Alterations induced by glucose and leptin in 13C-PA triacylglycerides and 13C-PA phospholipids were influenced by fetal sex and gestational diabetes status, but were all still attenuated by myo-inositol co-incubation. Insulin differently affected 13C-PA triacylglycerides and 13C-PA phospholipids depending on fetal sex, with alterations also attenuated by myo-inositol co-incubation.
KW - beta-oxidation
KW - fatty acid
KW - fetal sex
KW - gestational diabetes
KW - placental metabolism
KW - stable isotope
UR - https://www.scopus.com/pages/publications/85168385292
U2 - 10.1113/JP285036
DO - 10.1113/JP285036
M3 - Article
C2 - 37602663
AN - SCOPUS:85168385292
SN - 0022-3751
VL - 601
SP - 4151
EP - 4169
JO - Journal of Physiology
JF - Journal of Physiology
IS - 18
ER -